| BOUL Stock | | | SEK 7.00 0.38 5.15% |
Director
Mr. Kiarash Farr was appointed Director of Commercial Operations at Boule Diagnostics AB effective as of March 1, 2018. He previously was Head of Commercial Operations EMEA at Hycor Biomedical LLC. Before that, he worked as Sales Director Key Account at Thermo Fisher Scientific, Global Sales Director, Director of Global Business Development and Sales Director Asia Pacific at IBA, Sales Manager at Scanditronix Wellhofer, as well as Product Development Manager at Scanditronix Medical. He is Civil Engineer in Engineering Physics from Kungliga Tekniska Hogskolan. He has also studied Medical Engineering at Karolinska University Hospital and management at INSEAD in France. since 2018.
| Tenure | 6 years |
| Phone | 46 87 44 77 00 |
| Web | https://www.boule.com |
Boule Diagnostics Management Efficiency
The company has return on total asset
(ROA) of
0.0271 % which means that it generated a profit of $0.0271 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
0.0335 %, meaning that it generated $0.0335 on every $100 dollars invested by stockholders. Boule Diagnostics' management efficiency ratios could be used to measure how well Boule Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities.
Boule Diagnostics AB has accumulated 50.6
M in total debt with debt to equity ratio
(D/E) of 46.0, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Boule Diagnostics has a current ratio of 1.27, suggesting that it
is in a questionable position to pay out its financial obligations in time and when they become due. Debt can assist Boule Diagnostics until it has trouble settling it off, either with new capital or with free cash flow. So, Boule Diagnostics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Boule Diagnostics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Boule to invest in growth at high rates of return. When we think about Boule Diagnostics' use of debt, we should always consider it together with cash and equity.
Boule Diagnostics AB , a diagnostics company, develops, manufactures, and markets instruments and consumable products for blood diagnostics. Boule Diagnostics AB was founded in 1956 and is headquartered in Spnga, Sweden. Boule Diagnostics operates under Image Processing classification in Sweden and is traded on Stockholm Stock Exchange. Boule Diagnostics AB (BOUL) is traded on Stockholm Exchange in Sweden and employs 200 people.
Management Performance
Boule Diagnostics Leadership Team
Elected by the shareholders, the Boule Diagnostics' board of directors comprises two types of representatives: Boule Diagnostics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Boule. The board's role is to monitor Boule Diagnostics' management team and ensure that shareholders' interests are well served. Boule Diagnostics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Boule Diagnostics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Annette Colin, VP CFO | |
| Helena Borjesson, Chief Officer | |
| Kiarash Farr, Director of Commercial Operations | |
| Karen Bornstein, North Marketing | |
| Aishat Bislieva, VP Culture | |
| Jesper Soderqvist, CEO Pres | |
| Mikael Ekholm, VP Production | |
| Michael Eliott, Head Consumables | |
| Mattias Isaksson, VP Marketing | |
| Christina Hugosson, Head Systems | |
Boule Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Boule Diagnostics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Additional Tools for Boule Stock Analysis
When running Boule Diagnostics' price analysis, check to
measure Boule Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Boule Diagnostics is operating at the current time. Most of Boule Diagnostics' value examination focuses on studying past and present price action to
predict the probability of Boule Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Boule Diagnostics' price. Additionally, you may evaluate how the addition of Boule Diagnostics to your portfolios can decrease your overall portfolio volatility.